Call for Chapters: Global Perspectives on Antiviral Drug Development

Editors

Muhammad Shahzad Aslam, Xiamen University Malaysia, Malaysia
Bancha Yingngam, Ubon Ratchathani University, Thailand
Tariq Javed, GC University, Pakistan
Sana Riaz, Pakistan Council of Science and Industrial Research, Pakistan

Call for Chapters

Proposals Submission Deadline: September 29, 2024
Full Chapters Due: December 1, 2024
Submission Date: December 1, 2024

Introduction

In the face of rapidly evolving viral threats, from pandemics like COVID-19 to emerging viral diseases such as MERS, Zika, and Monkeypox, the global landscape of antiviral drug development has become increasingly complex and vital. Global Perspectives on Antiviral Drug Development comprehensively explores how different countries and regions have developed, deployed, and managed antiviral drugs. This book delves beyond the science to examine the strategies, policies, and innovations that shape public health responses to viral diseases worldwide. It serves as a critical resource for understanding the multifaceted challenges and opportunities in antiviral drug development, offering insights into the field's current state and future directions.

Objective

This book offers an evidence-based understanding of global antiviral strategies by integrating scientific innovation with policy analysis. By providing in-depth case studies, exploring cutting-edge technologies such as CRISPR and AI-driven drug discovery, and analyzing regulatory landscapes and public health implications, the book aims to inform and guide professionals in the field. The objectives for 2024 are to: 1-Enhance Evidence-Based Knowledge: Provide a comprehensive, data-driven overview of how various regions address viral threats, with actionable insights applicable globally. 2-Facilitate Innovation: Highlight and encourage the application of revolutionary technologies and approaches in antiviral drug development, grounded in the latest research and evidence. 3-Support Informed Policy Development: Equip policymakers with the insights needed to navigate the complexities of antiviral drug regulation and public health strategies, backed by robust evidence. 4-Improve Public Health Outcomes: Address social, economic, and ethical challenges to ensure broad access to antiviral drugs, contributing to better global health outcomes through evidence-based practices.

Target Audience

Public Health Professionals: Individuals involved in global health or policy-making who require the tools and insights to make informed decisions about antiviral strategies. Students and Academics: Those studying public health, pharmaceutical sciences, or global health policy, seeking to deepen their understanding of antiviral drug strategies. Policy Makers and Health Administrators: Professionals responsible for designing and implementing health policies, who will benefit from navigating the complexities of antiviral drug regulation and distribution.

Recommended Topics

1-Global Case Studies of Antiviral Drug Strategies: Analysis of successful antiviral responses in different countries, such as South Korea’s rapid containment of viral outbreaks. 2-Innovations in Antiviral Drug Development: Exploration of breakthrough technologies like CRISPR, AI-driven drug discovery, and nanomedicine in antiviral therapies. 3-Policy and Regulation of Antiviral Drugs: Comparative analysis of drug regulation, patent laws, and pricing strategies across different regions. 4-Pandemic Preparedness and Response: Strategies for antiviral drug stockpiling and effective public health campaigns during pandemics. 5-Public Health and Accessibility: Addressing the challenges and solutions related to making antiviral drugs accessible in low-income regions. 6-Ethical Dilemmas in Antiviral Drug Distribution: Exploration of the ethical considerations in the distribution and prioritization of antiviral drugs. 7-Combatting Drug-Resistant Viruses: The need for new antiviral strategies to address the growing threat of drug-resistant viruses. 8-Broad-Spectrum Antivirals: The future of global health security and the development of broad-spectrum antiviral agents. 9-Global Collaboration for Antiviral Drug Innovation: The importance of cross-border partnerships and knowledge sharing in advancing antiviral drug development. 10-Antiviral Drug Discovery in Emerging Economies: Challenges and opportunities in developing antiviral drugs in resource-limited settings. 11-Vaccine and Antiviral Synergy: The role of vaccines in complementing antiviral treatments and reducing viral spread. 12-Antiviral Drug Delivery Systems: Advances in drug delivery technologies, including nanotechnology and targeted delivery for antiviral therapies. 13-Real-World Data and Antiviral Effectiveness: Utilizing real-world evidence to assess the effectiveness and safety of antiviral drugs post-approval. 14-Antiviral Therapeutics for Emerging Viruses: Developing drugs for newly emerging viral threats, including zoonotic viruses and novel pathogens. 15-Economic Impact of Antiviral Drug Development: Analyzing the cost-effectiveness and economic implications of developing and distributing antiviral drugs globally. 16-Antiviral Drugs in Pediatric Populations: Challenges and strategies for developing and administering antiviral therapies in children. 17-Personalized Medicine in Antiviral Therapy: Tailoring antiviral treatments based on genetic, environmental, and lifestyle factors. 18-Public Perception and Acceptance of Antiviral Drugs: Understanding and addressing public concerns, misinformation, and hesitancy related to antiviral treatments. 19-Regulatory Harmonization for Antiviral Drugs: Efforts to standardize and streamline antiviral drug approval processes across different regulatory environments. 20-Digital Health and Antiviral Treatment: Leveraging telemedicine, mobile health applications, and digital tools to enhance the delivery and monitoring of antiviral therapies.

Submission Procedure

Researchers and practitioners are invited to submit on or before September 29, 2024, a chapter proposal of 1,000 to 2,000 words clearly explaining the mission and concerns of his or her proposed chapter. Authors will be notified by October 13, 2024 about the status of their proposals and sent chapter guidelines.Full chapters of a minimum of 10,000 words (word count includes references and related readings) are expected to be submitted by December 1, 2024, and all interested authors must consult the guidelines for manuscript submissions at https://www.igi-global.com/publish/contributor-resources/before-you-write/ prior to submission. All submitted chapters will be reviewed on a double-anonymized review basis. Contributors may also be requested to serve as reviewers for this project.

Note: There are no submission or acceptance fees for manuscripts submitted to this book publication, Global Perspectives on Antiviral Drug Development. All manuscripts are accepted based on a double-anonymized peer review editorial process.

All proposals should be submitted through the eEditorial Discovery® online submission manager.



Publisher

This book is scheduled to be published by IGI Global (formerly Idea Group Inc.), an international academic publisher of the "Information Science Reference" (formerly Idea Group Reference), "Medical Information Science Reference," "Business Science Reference," and "Engineering Science Reference" imprints. IGI Global specializes in publishing reference books, scholarly journals, and electronic databases featuring academic research on a variety of innovative topic areas including, but not limited to, education, social science, medicine and healthcare, business and management, information science and technology, engineering, public administration, library and information science, media and communication studies, and environmental science. For additional information regarding the publisher, please visit https://www.igi-global.com. This publication is anticipated to be released in 2025.



Important Dates

September 29, 2024: Proposal Submission Deadline
October 13, 2024: Notification of Acceptance
December 1, 2024: Full Chapter Submission
January 5, 2025: Review Results Returned
February 2, 2025: Final Acceptance Notification
February 17, 2025: Final Chapter Submission



Inquiries

Muhammad Shahzad Aslam
Xiamen University Malaysia
aslam.shahzad@xmu.edu.my

Bancha Yingngam
Ubon Ratchathani University
bancha.y@ubu.ac.th

Tariq Javed
GC University
dr.tariqjaved@gcu.edu.pk

Sana Riaz
Pakistan Council of Science and Industrial Research
sanariazpk@gmail.com



Classifications


Education; Life Sciences; Medicine and Healthcare
Back to Call for Papers List